Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Cognition Therapeutics (CGTX)

Annual Return

Over the past 3 years, CGTX has had an average annual return of -19.15%, underperforming the benchmark SPY, which returned +19.62% annual.

Since Oct 8, 2021, CGTX has had an average annual return of -41.27%, underperforming the benchmark SPY, which returned +13.37% annual.

202620252024202320222021
-25.92%+92.53%-62.11%-11.86%-66.78%-50.51%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-19.21%-0%-30.33%+65.88%-6.38%-2.49%-13.10%-25.92%
2025+3.10%-37.10%-7.30%+1.21%-44.01%+29.95%+88.89%+314.60%-44.46%+32.64%-2.78%-22.45%+92.53%
2024+22.71%-8.83%-12.09%+4.98%+2.07%-14.87%-39.77%-28.86%-34.11%+0.82%-14.86%+74.29%-62.11%
2023-6.14%-18.79%+23.78%-10.12%+15.14%-10.72%-9.28%-6.62%-7.08%-22.25%-0.91%+66.74%-11.86%
2022-30.37%-30.24%-10.44%+0.74%-5.39%-19.49%-10.41%+8.45%-7.29%-6.32%+97.20%-40.20%-66.78%
2021-5.32%-28.21%-27.19%-50.51%

Drawdown analysis of Cognition Therapeutics (CGTX)

The maximum drawdown for the CGTX was -98.16%, occurring on May 30, 2025. This drawdown has not yet recovered.

The current CGTX drawdown is -92.30%.

Since Oct 8, 2021 CGTX has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-98.16%Nov 9, 2021891May 30, 2025OngoingOngoingOngoing
-6.81%Oct 8, 20215Oct 15, 202117Nov 9, 202122